Regression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathy

Diabetologia

Volumn 56, Issue 6, 2013, Pages 1444-1453

  Aranda, J ^a   Motiejunaite, R ^a,b   Silva, P ^c   Aiello, L P ^c   Kazlauskas, A ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b VILNIUS UNIVERSITY   (Lithuania)

^c JOSLIN DIABETES CENTER   (United States)

Author keywords

Basic science; Endothelium; Microvascular disease; Retinopathy

Indexed keywords

AUTOTAXIN; LYSOPHOSPHATIDIC ACID; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; RHO KINASE; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COW; DIABETIC RETINOPATHY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXPLANT; EYE DISEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; RETINA NEOVASCULARIZATION; SIGNAL TRANSDUCTION; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CATTLE; COLLAGEN; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; HUMANS; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; MIDDLE AGED; REACTIVE OXYGEN SPECIES; RETINA; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84877789910     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2884-2     Document Type: Article

References (47)

1. International Diabetes Federation (2011) IDF Diabetes Atlas, 5th edn. IDF, Brussels. Available from http://www.idf.org/diabetesatlas, accessed 20 Feb 2013
2. Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366:1227-1239
3. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124-136
4. Engerman RL, Kern TS (1995) Retinopathy in animal models of diabetes. Diabetes Metabol Rev 11:109-120
5. Aiello LP, Gardner TW, King GL et al (1998) Diabetic retinopathy. Diabetes Care 21:143-156
6. Gariano RF, Gardner TW (2005) Retinal angiogenesis in development and disease. Nature 438:960-966
7. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
8. Watanabe D, Suzuma K, Matsui S et al (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353:782-792
9. Frank RN (2004) Diabetic retinopathy. N Engl J Med 350:48-58
10. Silva PS, Cavallerano JD, Sun JK, Aiello LM, Aiello LP (2010) Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol 6:494-508
11. Cury CE Jr, Rodrigues EB, Meyer CH, Farah ME (2009) VEGF inhibitors and vitrectomy for diabetic vitreoretinopathy. Dev Ophthalmol 44:69-81
12. Iacono P, Battaglia Parodi M, Bandello F (2010) Antivascular endothelial growth factor in diabetic retinopathy. Dev Ophthalmol 46:39-53
13. Adamis AP, Altaweel M, Bressler NM et al (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113:23-28
14. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H (2008) Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 18:263-269
15. Preis I, Langer R, Brem H, Folkman J (1977) Inhibition of neovascularization by an extract derived from vitreous. Am J Ophthalmol 84:323-328
16. Felton SM, Brown GC, Felberg NT, Federman JL (1979) Vitreous inhibition of tumor neovascularization. Arch Ophthalmol 97:1710-1713
17. Lutty GA, Thompson DC, Gallup JY, Mello RJ, Patz A, Fenselau A (1983) Vitreous: an inhibitor of retinal extract-induced neovascularization. Invest Ophthalmol Vis Sci 24:52-56
18. Aoki J (2004) Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 15:477-489
19. Moolenaar WH, van Meeteren LA, Giepmans BN (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870-881
20. Nakanaga K, Hama K, Aoki J (2010) Autotaxin - an LPA producing enzyme with diverse functions. J Biochem 148:13-24
21. van Meeteren LA, Ruurs P, Stortelers C et al (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26:5015-5022
22. Nam SW, Clair T, Kim YS et al (2001) Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61:6938-6944
23. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML (2000) Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19:241-247
24. Yeh PT, Yang CM, Huang JS et al (2008) Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology 115(734-737):e731
25. Im E, Motiejunaite R, Aranda J et al (2010) Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression. Mol Cell Biol 30:2401-2410
26. Aranda J, Motiejunaite R, Im E, Kazlauskas A (2012) Diabetes disrupts the response of retinal endothelial cells to the angiomodulator lysophosphatidic Acid. Diabetes 61:1225-1233
27. Im E, Venkatakrishnan A, Kazlauskas A (2005) Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 16:3488-3500
28. Im E, Kazlauskas A (2007) Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 282:29122-29129
29. Im E, Kazlauskas A (2006) Regulating angiogenesis at the level of PtdIns-4,5-P(2). EMBO J 25:2075-2082
30. Saulnier-Blache JS, Girard A, Simon MF, Lafontan M, Valet P (2000) A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. J Lipid Res 41:1947-1951
31. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH (1993) The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 291(Pt 3):677-680
32. Nagasaki T, Gundersen GG (1996) Depletion of lysophosphatidic acid triggers a loss of oriented detyrosinated microtubules in motile fibroblasts. J Cell Sci 109(Pt 10):2461-2469
33. Park EY, Kazlauskas A (2012) Primary human endothelial cells secrete agents that reduce responsiveness to lysophosphatidic acid (LPA). Biosci Rep 32:393-400
34. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M (2002) Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 134:348-353
35. Im E, Kazlauskas A (2006) New insights regarding vessel regression. Cell Cycle 5:2057-2059
36. Mavria G, Vercoulen Y, Yeo M et al (2006) ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Canc Cell 9:33-44
37. Kowluru RA, Odenbach S (2004) Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 45:4161-4166
38. Groeger G, Mackey AM, Pettigrew CA, Bhatt L, Cotter TG (2009) Stress-induced activation of Nox contributes to cell survival signalling via production of hydrogen peroxide. J Neurochem 109:1544-1554
39. Garay RP, Hannaert P, Chiavaroli C (2005) Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 4:221-232
40. Kowluru RA (2003) Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52:818-823
41. Spadea L, Balestrazzi E (2001) Treatment of vascular retinopathies with Pycnogenol. Phytother Res PTR 15:219-223
42. Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF (1998) Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley Diabetes Study. Ophthalmology 105:2264-2270
43. Millen AE, Klein R, Folsom AR, Stevens J, Palta M, Mares JA (2004) Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 79:865-873
44. Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD (2008) Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Canc Res 6:352-363
45. Rivera-Lopez CM, Tucker AL, Lynch KR (2008) Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11:301-310
46. Ausprunk DH, Falterman K, Folkman J (1978) The sequence of events in the regression of corneal capillaries. Lab Invest 38:284-294
47. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37:1625-1632